Pharmacy Vaccination 2026: UK vs European Models

Community pharmacy in Spain stands at a historical crossroads regarding its role in primary prevention. While regional vaccination schedules remain centralized in health centers, European experience demonstrates that pharmacists are key players in increasing population coverage rates.

The Current Framework of Vaccination in Spain in 2026

Nationwide, the dispensing of prescription-only vaccines is common, but direct administration in the pharmacy remains limited by highly disparate regional regulatory frameworks. Guidelines from the Spanish agency AEMPS and WHO recommendations endorse the safety of immunogens, but the lack of a unified state protocol hinders the pharmacist's full clinical integration (readers should consult their own national regulator for specific regulatory requirements).

When facing seasonal pathologies such as influenza or pneumococcus, the pharmacy counter acts as a fundamental point for health education and referral to primary care physicians. To optimize professional advice, health teams often rely on advanced resources such as the pharmacy vademecum and referral guidelines in minor ailments.

Lessons from European Models of Pharmaceutical Immunization

Countries such as the United Kingdom, Portugal, France, and Switzerland have demonstrated for years that allowing influenza and pneumococcal vaccination in community pharmacies decongests the national health system. In these countries, pharmacists receive accredited training in injection techniques and basic life support, integrating their records into the national electronic health record.

Evidence gathered by international agencies and reviewed by scientific committees shows a dramatic increase in risk groups when decentralized access is facilitated. Patients value proximity and the absence of prior appointments, which substantially improves preventive pharmaceutical care and reduces severe complications derived from low coverage.

Safety Criteria and Active Pharmacovigilance

Any strategy for expanding competencies requires a rigorous system for reporting post-vaccination adverse reactions (ADRs). Pharmacovigilance bulletins and alerts from official bodies are routinely consulted by professionals to monitor the safety of biological preparations available on the market.

Likewise, when administering combination preparations or in polymedicated patients, it is essential to check for possible contraindications or special precautions using a rigorous interaction checker, thus guaranteeing maximum clinical safety for the citizen prior to the issuance of any recommendation or referral to the prescribing physician.